SHIEF - Shield Therapeutics couldn't be more pleased with Viatris collaboration
(NewsDirect)
Shield Therapeutics PLC (AIM:STX,OTCQX:SHIEF) CEO Greg Madison speaks to Thomas Warner after a busyweek for the commercial stage pharmaceutical company, which includedthe release of its interim results and the announcement of a majorfundraise.
He highlights the successof the fundraise, which comprised US$20 million from a new senior debtfacility as well as an equity fundraise (split between a shareplacing, a subscription and an offering to retail investors) thatbrought in an additional US$6 million.
He explains that the new funding is going to be put to use in"paying off an existing loan, increasing our working capital needsand then certainly some commercial investments to accelerate the curvethat we're seeing here."
Thecurve he describes is the marked increase in demand for Shield'sAccrufer product, which is a stable, non-salt based oral therapy foradults with iron deficiency that is designed to avoid some of theunwanted side-effects of conventional iron tablets.
He says he"can't speak highly enough about the dedication and passion of[his] team at Shield, but also about our partner Viatris... we made anexcellent choice... we couldn't be more pleased with thepartnership and the collaboration we're seeing."
Contact Details
Proactive UK Ltd
+44 207989 0813
Copyright (c) 2023 TheNewswire - All rights reserved.